STRIDES PHARMA SCIENCE
|
|
BOM : 532531     NSE : STAR     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : High [>50%] |
Oct 10,2024 |
Price(EOD): ₹ 1,516.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 13,950.88 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
STRIDES PHARMA SCIENCE | 4.3% | 12.2% | 200.9% |
SUN PHARMACEUTICAL INDUSTRIES | -1.2% | 2.8% | 71.4% |
CIPLA | -0.3% | -0.8% | 44.6% |
DR REDDYS LABORATORIES | -0.8% | -1% | 23% |
ZYDUS LIFESCIENCES | -0% | -5% | 76.5% |
DIVIS LABORATORIES | 9.6% | 9.4% | 60.9% |
FUNDAMENTAL ANALYSIS OF STRIDES PHARMA SCIENCE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF STRIDES PHARMA SCIENCE
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
166.5
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 83.75 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 6.57
P/B Calculated based on Book Value of Rs 2,122.47 Cr
[Latest Year - Mar2024 - Consolidated Results ] 3.31
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,208.63 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
766% 29% 46% |
SHARE PRICE MOMENTUM OF STRIDES PHARMA SCIENCE
STRIDES PHARMA SCIENCE vs SENSEX
DEBT OF STRIDES PHARMA SCIENCE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.45 0.39 0.37 0.4 |
1.14 1.27 1.18 1.2 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF STRIDES PHARMA SCIENCE
Pledged Promoter Shares |
69.17 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF STRIDES PHARMA SCIENCE
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.32% -5.55% 24.01% 35.91% |
16.94% 30.25% 191.68% 239.92% |
QtrlyTrend |
6 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
STRIDES PHARMA SCIENCE related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.7% | 1.6% | 57.8% |
S&P BSE SMALL CAP | -0.1% | 1.3% | 49.7% |
S&P BSE MIDSMALLCAP | -0.2% | 0.6% | 50.5% |
S&P BSE ALLCAP | -0.6% | 0.3% | 37.5% |
You may also like the below Video Courses
FAQ about STRIDES PHARMA SCIENCE
Is STRIDES PHARMA SCIENCE good for long term investment?
As on Oct 10,2024, the Fundamentals of STRIDES PHARMA SCIENCE look Poor and hence it may not be good for long term investment ! See Financial Performance of STRIDES PHARMA SCIENCE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is STRIDES PHARMA SCIENCE UnderValued or OverValued?
As on Oct 10,2024, STRIDES PHARMA SCIENCE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of STRIDES PHARMA SCIENCE ?
As on Oct 10,2024, the Intrinsic Value of STRIDES PHARMA SCIENCE is Rs. 1,037.45 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 175.18
Fair Value [Median EV / Sales Model] : Rs. 1,179.12
Fair Value [Median Price / Sales Model] : Rs. 1,037.45
Estimated Median Fair Value of STRIDES PHARMA SCIENCE : Rs. 1,037.45
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.